Figure 4

Different measures of the cumulative burden of subsequent malignancies and cardiovascular disease by treatment modality. For patients receiving no anthracyclines and no alkylating chemotherapy (except low-dose procarbazine), (A) the cumulative incidence of developing subsequent malignancy or cardiovascular disease as first event and (B) the mean cumulative count for all subsequent malignancies and cardiovascular diseases by radiotherapy field are shown. For patients receiving anthracycline-containing chemotherapy, (C) the cumulative incidence of developing subsequent malignancy or cardiovascular disease as first event and (D) the mean cumulative count for all subsequent malignancies and cardiovascular diseases by radiotherapy field are shown. Incomplete mantle field radiotherapy is only shown in the graphs for patients receiving anthracycline-containing chemotherapy because in the anthracycline era smaller radiotherapy fields were introduced.